Literature DB >> 8815011

Antitumor and antimetastatic activity of interleukin-12.

J A Hendrzak1, M J Brunda.   

Abstract

Mesh:

Substances:

Year:  1996        PMID: 8815011     DOI: 10.1007/978-3-642-80071-9_5

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


× No keyword cloud information.
  4 in total

1.  Focused ultrasound-induced blood-brain barrier opening to enhance interleukin-12 delivery for brain tumor immunotherapy: a preclinical feasibility study.

Authors:  Pin-Yuan Chen; Han-Yi Hsieh; Chiung-Yin Huang; Chun-Yen Lin; Kuo-Chen Wei; Hao-Li Liu
Journal:  J Transl Med       Date:  2015-03-17       Impact factor: 5.531

2.  Membrane-bound p35 Subunit of IL-12 on Tumor Cells is Functionally Equivalent to Membrane-bound Heterodimeric Single Chain IL-12 for Induction of Anti-tumor Immunity.

Authors:  Hyun-Jin Kim; Sang Min Park; Hayyoung Lee; Young Sang Kim
Journal:  Immune Netw       Date:  2016-10-25       Impact factor: 6.303

3.  Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells.

Authors:  Hong Luo; Xiuqi Wu; Ruixin Sun; Jingwen Su; Yi Wang; Yiwei Dong; Bizhi Shi; Yansha Sun; Hua Jiang; Zonghai Li
Journal:  Front Oncol       Date:  2019-12-19       Impact factor: 6.244

Review 4.  Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future.

Authors:  Zhengchao Zhang; Lele Miao; Zhijian Ren; Futian Tang; Yumin Li
Journal:  Front Immunol       Date:  2021-07-27       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.